Clinical trials: Patients With Type 2 Diabetes
Diabetes Mellitus
Evaluating Glucose Control Using a Next Generation Automated Insulin Delivery Algorithm in Patients With Type 1 and Type 2 Diabetes
To assess the safety and effectiveness of a next-generation automated insulin delivery algorithm in participants aged 16+ years with type 1 or type 2 diabetes.
- Trial name
- Evolution (NCT06181721)
- Testing
- Omnipod 5 Automated Glucose Control System
- Where
- New Zealand
- Volunteers
- 20 people
- Sponsor
- Insulet Corporation
Diabetes Mellitus, Non-Insulin-Dependent
Evaluate the Role of Adding Amaryl to Non-Insulin Dependent Diabetes Mellitus Patients Unresponsive to Maximum Dose Metformin & Thiazolidinedione
The purpose of this study is to assess the efficacy and safety of Amaryl when added to Metformin and Thiazolidinedione (TZD) in non-insulin dependent diabetes mellitus (NIDDM) patients.
- Trial name
- NCT00044447
- Testing
- Glimepiride
- Where
- United States
- Volunteers
- 170 people
- Sponsor
- Sanofi
Obesity (Disorder), GLP-1 Receptor Agonist Treatment
Probiotics in Obese Patients Treated With Semaglutide
This randomized, double-blind, placebo-controlled trial evaluated the effects of a four-strain probiotic formulation in adults with obesity receiving semaglutide.
- Conditions
- Obesity (Disorder), GLP-1 Receptor Agonist Treatment, Probiotic Intervention, Diabetes Mellitus Type 2
- Trial name
- ProSem (NCT07847593)
- Testing
- Four-strain probiotic formulation
- Where
- 3 sites in Poland
- Volunteers
- 102 people
- Sponsor
- Nordic Biotic Sp. z o.o.
Type 2 Diabetes
Chiglitazar Added to Metformin for Type 2 Diabetes
The purpose of the trial is to evaluate the effect of Chiglitazar added to metformin to type 2 diabetes Inadequately controlled with metformin Monotherapy.
- Trial name
- NCT04807348
- Testing
- Chiglitazar 32mg, Chiglitazar 48mg, Metformin Hydrochloride
- Where
- 50 sites in China
- Volunteers
- 533 people
- Sponsor
- Chipscreen Biosciences, Ltd.
Diabetes Mellitus, Type 2, Insomnia
A Study of the Efficacy of Prolonged-Release Melatonin Versus Placebo in Diabetic Patients Suffering From Insomnia
Objective - Type 2 uncontrolled diabetic patients often have low endogenous melatonin and suffer from sleep disorders. The effect of a prolonged-release melatonin (PRM) formulation on glucose lipid metabolism and sleep is studied…
- Trial name
- NCT00869128
- Testing
- Circadin
- Volunteers
- 36 people
- Sponsor
- Neurim Pharmaceuticals Ltd.
Diabetes Mellitus Type 2
Effect of DapagliFLOzin on Quality of Life in Patients With Type 2 Diabetes in a Real Clinical PrActice
This is a multicenter, randomised, open-label, crossover, 2-period comparative phase IV study. The primary objective is to compare the effect of dapagliflozin 10 mg once daily in combination with metformin at a daily dose of…
- Trial name
- FLORA (NCT02719132)
- Testing
- Dapagliflozin, Metformin
- Sponsor
- AstraZeneca
Diabetes Mellitus
Efficacy and Safety Study of TAK-559 in Treating Subjects With Type 2 Diabetes Mellitus
The purpose of this study was to determine the safety and efficacy of TAK-559, once daily (QD), in treating subjects with type 2 diabetes mellitus.
- Trial name
- NCT00762684
- Testing
- TAK-559
- Volunteers
- 8 people
- Sponsor
- Takeda
Diabetes Mellitus, Type 2
Cardiovascular and Renal Microvascular Outcome Study With Linagliptin in Patients With Type 2 Diabetes Mellitus (CARMELINA)
The aim of the study is to investigate the longterm impact on cardiovascular morbidity, mortality and renal function of treatment with linagliptin in a selected population of patients with Type 2 diabetes mellitus (T2DM) and to…
- Trial name
- NCT01897532
- Testing
- Linagliptin
- Where
- 649 sites in United States, Argentina and 25 more
- Volunteers
- 6,991 people
- Sponsor
- Boehringer Ingelheim
Type 2 Diabetes Mellitus (T2DM)
A Study to Evaluate the Efficacy and Safety of AD-233A, AD-233B, AD-233C and/or AD-233D Combination Therapy
The purpose of this study is to evaluate the efficacy and safety of AD-233A, AD-233B, AD-233C and/or AD-233D combination therapy
- Trial name
- NCT07816198
- Testing
- AD-233A, AD-233B, AD-233C
- Volunteers
- 354 people
- Sponsor
- Addpharma Inc.
Adult Patients With Type 2 Diabetes Uncontrolled on Oral Antidiabetic Drugs
A Study Comparing HR17031 With Insulin Glargine in Patients With Type 2 Diabetes
The aim of this trial is to confirm the efficacy of HR17031 in controlling glycaemia in Chinese subjects with type 2 diabetes mellitus inadequately controlled on oral antidiabetic agents
- Trial name
- NCT06881264
- Testing
- HR17031 injection, insulin glargine
- Where
- China
- Volunteers
- 401 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Diabetes, Diabetes Mellitus, Type 2
Observational Study to Observe the Safety of NovoMix® 30 Treatment in Patients With Type 2 Diabetes
This study is conducted in Europe. The study aims to observe the incidence of serious adverse drug reactions in patients with type 2 diabetes during NovoMix® 30 treatment.
- Trial name
- NCT00729898
- Testing
- biphasic insulin aspart 30
- Where
- 2 sites in Norway, Sweden
- Volunteers
- 243 people
- Sponsor
- Novo Nordisk A/S
Diabetes Mellitus Type 2
Comparative Effectiveness of Cardiovascular Outcomes in New Users of SGLT-2 Inhibitors
CVD-REAL is a multinational, observational cohort study in patients with type 2 diabetes mellitus evaluating the comparative effectiveness of initiating treatment with a sodium-glucose co-transporter-2 (SGLT-2) inhibitor versus…
- Trial name
- CVD-REAL (NCT02993614)
- Where
- 17 sites in United States, Australia and 15 more
- Volunteers
- 99,999 people
- Sponsor
- AstraZeneca
Diabetes Mellitus, Type 2
A Non Interventional Study to Monitor the Safety and Effectiveness of Trajenta (Linagliptin, 5 mg, q.d) in Korean Patients With Type 2 Diabetes Mellitus
The aim of this study is to monitor safety and efficacy of treatment with linagliptin in Korean patients with type 2 diabetes mellitus in routine clinical settings.
- Trial name
- NCT01707147
- Testing
- Trajenta tablet
- Where
- South Korea
- Volunteers
- 3,219 people
- Sponsor
- Boehringer Ingelheim
Diabetes Mellitus, Type 2
GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Basal Insulin +/- Sulfonylurea (GETGOAL-L-ASIA)
The purpose of this study is to evaluate the benefits and risks of lixisenatide (AVE0010), in comparison to placebo, as an add-on treatment to basal insulin with or without sulfonylurea, over a period of 24 weeks of treatment.
- Trial name
- GETGOAL-L-ASIA (NCT00866658)
- Testing
- Lixisenatide (AVE0010), Pen auto-injector, Sulfonylurea
- Where
- 4 sites in Japan, Philippines and 2 more
- Volunteers
- 311 people
- Sponsor
- Sanofi
Type 2 Diabetes
Effect of Treatment With Insulin VIAjectTM Compared to Regular Human Insulin and Insulin Lispro on Mealtime Blood Vessel Stress in Patients With Type 2 Diabetes Mellitus.
The purpose of this study is to compare the effects of insulin VIAject with Regular Human Insulin and Insulin Lispro on measures of mealtime blood vessel stress and blood flow.
- Trial name
- NCT00849576
- Testing
- Regular Human Insulin, Insulin Lispro, Insulin VIAject™ (75%)
- Where
- Germany
- Volunteers
- 15 people
- Sponsor
- Biodel
Type 2 Diabetes Mellitus
MK0431 (Sitagliptin) Pioglitazone Add-on Study for Patients With Type 2 Diabetes Mellitus (0431-055)(COMPLETED)
The clinical study determines the safety and efficacy of MK0431 in patients with type 2 diabetes mellitus who have inadequate glycemic control on pioglitazone as monotherapy.
- Trial name
- NCT00372060
- Testing
- sitagliptin phosphate, Comparator: sitagliptin phosphate (MK0431), Comparator: pioglitazone
- Volunteers
- 134 people
- Sponsor
- Merck Sharp & Dohme LLC
Type 2 Diabetes Mellitus
Efficacy and Safety of Sotagliflozin Versus Placebo in Patients With Type 2 Diabetes Mellitus on Background of Metformin
Primary Objective: To demonstrate the superiority of Sotagliflozin versus placebo on hemoglobin A1c (HbA1c) reduction in participants with type 2 diabetes (T2D) who have inadequate glycemic control with metformin.
- Trial name
- NCT02926950
- Testing
- Sotagliflozin (SAR439954), Metformin
- Where
- 93 sites in United States, Canada and 2 more
- Volunteers
- 518 people
- Sponsor
- Lexicon Pharmaceuticals
Depression, Postpartum
Type II Diabetes Mellitus in Patients Exposed to Pravastatin and Paroxetine
Type 2 Diabetes (T2DM) is a life-long, chronic condition affecting an individuals' ability to regulate glucose levels in the blood. Diabetes can cause many severe complications if not treated properly.
- Trial name
- NCT01602913
- Testing
- Pravastatin alone, Paroxetine alone, Pravastatin and paroxetine combined
- Volunteers
- 1 people
- Sponsor
- GlaxoSmithKline
Diabetes Mellitus, Type 2
A Research Study of How Semaglutide Works in People With Disease Affecting the Heart and/or Blood Vessels and Type 2 Diabetes
This study looks into how the type 2 diabetes medicine, semaglutide, can prevent risk of heart disease complications and stroke.
- Trial name
- NCT04032197
- Testing
- Semaglutide
- Where
- 4 sites in Austria, Denmark and 1 more
- Volunteers
- 101 people
- Sponsor
- Novo Nordisk A/S
Chronic Kidney Disease, Type 2 Diabetes
A Glomerular Filtration Rate (GFR) Measuring Study of RTA 402 in Chronic Kidney Disease (CKD) Patients With Type 2 Diabetes Mellitus
A Phase 2 glomerular filtration rate (GFR) measuring study of RTA 402 in Chronic kidney disease (CKD) patients with type 2 diabetes mellitus.
- Trial name
- NCT01572610
- Testing
- RTA 402
- Where
- Japan
- Volunteers
- 11 people
- Sponsor
- Kyowa Kirin Co., Ltd.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.